Publications

News

Life Sciences and Health Care Horizons 2019 publication: IP in the mix

Innovation in the life sciences and health care industries is occurring at a dizzying pace. Five years ago, anti-PD-1 antibodies from Merck and BMS had yet to be approved, CAR-T therapies ...

News

Data commercialisation strategy: A drill-down with Financier Worldwide

In thisnew article in Financier Worldwide, IP Partners Zenas J. Choi and Cullen G. Taylor take a look at how businesses should develop strategies to turn a wealth of raw data into...

Published Works

Optimal data commercialisation: transforming raw data into revenue-generating insights Financier Worldwide

Partners Zenas Choi and Cullen Taylor co-authored an article titled: "Optimal data commercialisation: transforming raw data into revenue-generating insights" published on Financier...

News

Looking Ahead at AI’s Effect on IP in the Pharma Sector

In April’s issue of Pharma Times Magazine, partner Cullen Taylor explores how new machine learning technologies may have far-reaching, unexpected effects on IP and patent law.

Hogan Lovells Publications

Digital Health: The issues you need to consider to leverage its full potential in 2018 Life Sciences Team

Technology is changing the way the healthcare industry operates, bringing huge potential for untapped business opportunity. At the same time, with these changes comes a dramatic shift in...

Hogan Lovells Publications

U.S. – What does the Impression Products v. Lexmark decision mean for drug companies? 5 takeaways LimeGreen IP News

Last May, the U.S. Supreme Court issued a highly-anticipated decision in Impression Products, Inc. v. Lexmark Int’l, Inc., reversing the Federal Circuit and holding that, when a...

Hogan Lovells Publications

U.S. – Protecting IP in digital health deals LimeGreen IP News

Industry sources estimate that more than US$4 billion worth of deals in digital health have been signed globally this year so far, as pharmaceutical manufacturers look for "beyond the pill" ...

Hogan Lovells Publications

New FDA draft guidance on Contract Manufacturing Quality Agreements Pharmaceuticals and Biotechnology Alert

On 28 May 2013, FDA issued a draft guidance for the industry, titled Contract Manufacturing Arrangements for Drugs: Quality Agreements. The release of this draft guidance is important...

Loading data